Equillium Reports Second Quarter 2019 Financial Results and Recent Highlights
12 août 2019 16h07 HE
|
Equillium
Initiated Phase 1b EQUIP proof-of-concept trial evaluating itolizumab (EQ001) for the treatment of uncontrolled asthma Investigational New Drug (IND) application accepted by FDA for itolizumab for...
Equillium Announces Initiation of the EQUIP Phase 1b Clinical Trial of Itolizumab for Patients with Uncontrolled Asthma
10 juil. 2019 08h07 HE
|
Equillium
LA JOLLA, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Manual Resuscitators Market To Reach USD 640.4 Million by 2026 | Reports And Data
10 juin 2019 10h20 HE
|
Reports And Data
Factors contributing to high CAGR are utilization of flow-inflating neonatal care and intensive care units. Moreover, technological progressions, product launches and partnerships have further fueled...
Equillium to Present at Jefferies 2019 Healthcare Conference
23 mai 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., May 23, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Reports First Quarter 2019 Financial Results and Recent Highlights
13 mai 2019 16h07 HE
|
Equillium
EQUATE Phase 1b/2 trial in acute graft-versus-host disease (aGVHD) ongoing with data expected in 1Q 2020 On track to initiate Phase 1b proof-of-concept trials of itolizumab (EQ001) in uncontrolled...
Equillium Expands Scientific and Clinical Advisory Team
06 mai 2019 08h30 HE
|
Equillium
LA JOLLA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium to Present at Solebury Trout Class of 2018 Biotech IPO Investor Day
16 avr. 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., April 16, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Bruce...
Dry Powder Inhaler Device Market to Reach USD 912.3 Million By 2026
01 avr. 2019 11h03 HE
|
Reports And Data
Increase in ageing population who are prone to or has risk of respiratory infections will boost market growth; increasing incidences of hereditary diseases, lung disorders and increasing pollution due...
Equillium to Present at H.C. Wainwright Global Life Sciences Conference
28 mars 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan...
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
27 mars 2019 16h07 HE
|
Equillium
LA JOLLA, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...